inc.

Top Biotechnology Stock Picking: Genocea Biosciences, Inc. (GNCA), Baxalta …
www.zergwatch.com

Genocea Biosciences, Inc. (GNCA) on March 31, 2016 announced positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. GEN-003 demonstrated sustained and statistically significant …

9
Like
Save
Valeant Pharmaceuticals International, Inc. ($VRX) Stock | Shares Plummet On …
ticker.tv

It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine …

2
Like
Save
Valeant Pharmaceuticals International, Inc. ($VRX) Stock | Stock Sinks On …
ticker.tv

It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine …

5
Like
Save
NanoViricides, Inc. (NNVC) Targeting Commercially Important Viral Diseases …
www.investorideas.com

Although NNVC's licensed technology may be effective in combatting a host of viruses – including HIV/AIDS, cold sores and genital herpes infection, viral eye diseases and dengue viruses – the company's leading product candidate is being developed for …

6
Like
Save
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) near 52-week low, short …
www.streetreport.co

The company also provides Zovirax ointment to treat initial genital herpes; Xerese to treat recurrent herpes labialis; Elidel to treat atopic dermatitis; and Acanya and Atralin gels to treat acne vulgaris. In addition, it offers Cesamet to treat nausea …

3
Like
Save
Moving Stocks: Intermolecular, Inc. (NASDAQ:IMI), Emerson Electric Co. (NYSE …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

9
Like
Save
Top Stories: Nivalis Therapeutics, Inc. (NASDAQ:NVLS), Itau Unibanco Holding …
www.stocktranscript.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Biotech Decliners: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ContraVir …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

5
Like
Save
Biotech Stocks with Active Concerns: Genocea Biosciences, Inc. (NASDAQ:GNCA …
www.senecaglobe.com

… cell-directed vaccines and immunotherapies, recently reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of …

3
Like
Save
Stocks in News: Great Basin Scientific, Inc. (NASDAQ:GBSN), Genocea …
www.stocktranscript.com

It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria.

9
Like
Save